$コンパス・パスウェイズ(CMPS.US)$ NEWS Compass Pathways announces durable improvement in symptoms through 12 weeks in open-label phase 2 study of COMP360 psilocybin in post-traumatic stress disorder
$コンパス・パスウェイズ(CMPS.US)$ NEWS Compass Pathways establishes research collaboration with Mindful Health Solutions to inform the development of a scalable and cost-effective delivery model for investigational COMP360 psilocybin treatment
Cody Shandraw of Ambria Capital suggests FDA approval for MDMA legalization could be imminent, asserting that MDMA therapy might follow a similar trajectory to JNJ's Spravato treatment for depression. He is thrilled about the potential coverage of the therapy by the U.S. Department of Veterans Affairs for military personnel.
PYUN970IHaveChosen :
IKR WTF! I have been watching and holding ATAI/CMPS/CYBN! ATAI is ! Now check the MUSK Depression FIGHT! (I’d depressed if I couldn’t figure out how to spend all that money as well, LMAO) nothing wrong with some Microdosing!
コンパス・パスウェイズに関するコメント
NEWS
Compass Pathways announces durable improvement in symptoms through 12 weeks in open-label phase 2 study of COMP360 psilocybin in post-traumatic stress disorder
NEWS
Compass Pathways establishes research collaboration with Mindful Health Solutions to inform the development of a scalable and cost-effective delivery model for investigational COMP360 psilocybin treatment
• $ジェンコ シッピング&トレーディング(GNK.US)$ +4.7% (positive Barrons article)
• $ネクストデケード(NEXT.US)$ +4.7% (files for 4618226 share common stock offering by selling shareholder)
• $コンパス・パスウェイズ(CMPS.US)$ +4.7% (COMPASS Pathways presents largest ever study of psilocybin therapy at American Psychiatric Association annual meeting)
• $カヌー(GOEV.US)$ +3.5% (files for 48043111 share common stock offering by selling shareholder)
• $アメリカン アクスル アンド マニュファクチャリング ホールディングス(AXL.US)$ +3.7% (pr...
$シビン(CYBN.US)$ $エンベリック バイオサイエンシズ(ENVB.US)$ $マインド メディシン マインドメッド(MNMD.US)$ $シーロス セラピ(SEEL.US)$ $コンパス・パスウェイズ(CMPS.US)$ $ADVISORSHARES PSYCHEDELICS ETF(PSIL.US)$ building up short positions. The whole sector has taken a huge smack regardless of the fda approvels, Cybin having a clinic in New York. Envb having its Psy-ai. Seelos is up big without any indication of why. Mind med is down, started more studies on mdma and lsd. Get ready and load up. Things are looking strange.
Since early 2020, the industry for medicinal psychedelic drugs received an extraordinary injection of capital, launching several companies in major exchanges like the NYSE and the Nasdaq, some of which now have valuations of over $1 billion.
Psychedelics Companies Listed On The Nasdaq And NYSE
Atai Life Sciences ( $アタイ ライフ サイエンシズ(ATAI.US)$ )
Compass Pathways ( $コンパス・パスウェイズ(CMPS.US)$ )
MindMed ( $マインド メディシン マインドメッド(MNMD.US)$ )
Field Trip Health, Inc. ( $FIELD TRIP HEALTH LTD(FTRP.US)$ )
Seelos Therapeutics ( $シーロス セラピ(SEEL.US)$
Enveric Biosciences ( $エンベリック バイオサイエンシズ(ENVB.US)$ )
Pasithea Therapeutics Corp. ( $パスィセア セラピューティクス(KTTA.US)$ )
GH Research ( $コヘラス バイオサイエンス(CHRS.US)$ )
Cybin Corp ( $シビン(CYBN.US)$ )
MMEDF
CLABF
LKYSF
TWGL
SHRMF
PSYCHEDELIC . MENTAL HEALTH. TREATMENT?
NONE BELIEVEFS STEP FAR BACK.
まだコメントはありません